Immunotherapy with subcutaneous immunoglobulin or plasmapheresis in patients with postural orthostatic tachycardia syndrome (POTS)

• Published in: Journal of neurology 2023, Vol.270 (1), p.233-239
• Main Authors: Kesterson, Katrina, Schofield, Jill, Blitshteyn, Svetlana
• Format: Article
• Language: English
• Subjects: Autoimmunity; Autonomic nervous system; Biopsy; Cardiac arrhythmia; Clinical trials; Humans; Immunoglobulins; Immunotherapy; Intravenous administration; Medicine; Medicine & Public Health; Morbidity; Neurology; Neuropathy; Neuroradiology; Neurosciences; Original Communication; Patients; Plasmapheresis; Postural Orthostatic Tachycardia Syndrome - complications; Postural Orthostatic Tachycardia Syndrome - diagnosis; Postural Orthostatic Tachycardia Syndrome - therapy; Posture; Retrospective Studies; Tachycardia
• ISSN: 0340-5354; 1432-1459
• DOI: 10.1007/s00415-022-11344-z

Background Postural orthostatic tachycardia syndrome (POTS), one of the most common autonomic disorders, is associated with significant morbidity and functional impairment. Although several possible etiologies have been proposed, autoimmunity has emerged as one of the leading causes with various specific and non-specific antibodies identified in patients with POTS. Treatment with intravenous immunoglobulin has been previously described. We present a case series of patients with severe POTS refractory to the standard pharmacologic and non-pharmacologic therapies treated with immunotherapy consisting of either subcutaneous immunoglobulin (SCIG) therapy or plasmapheresis (PLEX) and report their treatment outcomes. Methods Clinical history of 7 patients with POTS who were treated with SCIG or PLEX was reviewed. Response to treatment was assessed using COMPASS 31 and functional ability scale (FAS), completed by patients retrospectively, pre- and 3–12 months post-treatment with SCIG or PLEX. Results All patients improved following SCIG or PLEX with an average 50% reduction in COMPASS 31 score and 217% increase in FAS scores. Six out of seven patients were able to reduce or discontinue oral medications for POTS, and five patients were able to return to work or school. Four patients had skin biopsy or quantitative sudomotor axon reflex test (QSART)-proven small fiber neuropathy, and five had various positive antibodies at low titers. Conclusion Patients with severe, treatment-refractory POTS experienced significant functional improvement with reduction in the autonomic symptoms following immunotherapy with SCIG or PLEX. Randomized controlled trials of SCIG and/or PLEX are needed to determine the efficacy and safety of these long-term therapies in patients with POTS.